Comparison of Torasemide and Indapamide in the Treatment of Essential Hypertension

Spannbrucker, N.; Achhammer, I.; Häcker, W.

doi:10.1007/978-1-4613-2067-8_63

Cited by 4 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Long term administration of indapamide produces a hypotensive action at a dose which causes no significant alteration in body weight or plasma volume in man (Weidmann et al 1980). Torasemide shows an antihypertensive action at a non-diuretic dose in the hypertensive patient (Spannbrucker et al 1988). In contrast, the diuretic action of frusemide is the major mechanism of its hypotensive action.…”

Section: Discussionmentioning

confidence: 97%

“…Torasemide produces an antihypertensive action a t a lower dose than that which produces the diuretic action in man (Spannbrucker et al 1988). Thus, torasemide possesses an antihypertensive action independent of its diuretic one.…”

Section: Isopropyl-3-{ [4-(3-methyl-phenylamino)pyridine]-3-sulphonyl}mentioning

confidence: 97%

“…Torasemide exhibited a strong and longlasting diuretic action when compared with frusemide in man (Lesne 1988;Lupinacci & Puschett 1988) and normal animals (Uchida et al 1990). The pharmacological profile of torasemide shows less kaliuresis in comparison with frusemide at doses which give equivalent natriuresis and aquaresis (Ghys et al 1985;Delarge 1988).Torasemide produces an antihypertensive action a t a lower dose than that which produces the diuretic action in man (Spannbrucker et al 1988). Thus, torasemide possesses an antihypertensive action independent of its diuretic one.…”

mentioning

confidence: 95%

See 2 more Smart Citations

Torasemide, but not frusemide, increases intracellular cAMP and cGMP content in the aorta of the renal hypertensive rat

Yamanaga¹,

Uchida²,

Kido³

et al. 1992

Journal of Pharmacy and Pharmacology

View full text Add to dashboard Cite

Repeated oral administration of the novel loop diuretic torasemide (3 mg kg-1) and frusemide (30 mg kg-1) for 7 days, elicited a significant fall in the systolic blood pressure in the one-kidney, one-clip Goldblatt renal hypertensive rat (RHR). The hypotensive action was greater in the torasemide group than in the frusemide group. Furthermore torasemide increased intracellular cAMP and cGMP content in aorta of RHR. Frusemide caused no effect. It is hypothesized that the increase in adenosine- or guanosine-nucleotides is involved in the antihypertensive action of torasemide, but not in that of frusemide.

show abstract

Section: Discussionmentioning

confidence: 97%

Section: Isopropyl-3-{ [4-(3-methyl-phenylamino)pyridine]-3-sulphonyl}mentioning

confidence: 97%

mentioning

confidence: 95%

See 1 more Smart Citation

Torasemide, but not frusemide, increases intracellular cAMP and cGMP content in the aorta of the renal hypertensive rat

Yamanaga¹,

Uchida²,

Kido³

et al. 1992

Journal of Pharmacy and Pharmacology

View full text Add to dashboard Cite

show abstract

“…Data from both the short and long term hypertension studies [59][60][61][62][63] indicate that torasemide does not adversely affect blood glucose levels, even in diabetic patients. Blood glucose levels tended to increase with increasing torasemide dosage, and the mean changes from baseline for the 10 and 20 mg/day dosages [0.31 mmollL(5.5 mg/dl) and 0.26 mmollL (4.6 mg/dl), respectively] were significantly different from placebo.…”

Section: Bratermentioning

confidence: 99%

Benefits and Risks of Torasemide in Congestive Heart Failure and Essential Hypertension

1996

Drug Safety

View full text Add to dashboard Cite

Torasemide is a lipophilic anilinopyridine sulphonylurea derivative that acts as a high ceiling loop diuretic and has been used for the treatment of both acute and chronic congestive heart failure (CHF) and hypertension. Torasemide is similar to other loop diuretics in terms of its mechanism of diuretic action; namely, blockade of Na+/K+/2Cl- cotransport in the thick ascending limb of the loop of Henle. It has high bioavailability (> 80%), as does bumetanide, but a longer elimination half-life (3 to 4 hours) than either bumetanide or furosemide (frusemide). In the treatment of chronic CHF, oral torasemide (5 to 20 mg/day) has been shown to be an effective diuretic. Patients treated with torasemide for up to 1 year have reduced bodyweight, improved pulmonary haemodynamics, and decreased CHF severity. Intravenous torasemide (20 to 60mg as a single dose) has been shown to be as effective as furosemide in the treatment of acute CHF, and resulted in significant diuresis, bodyweight loss, and improved pulmonary haemodynamics and exercise performance. 'Non-diuretic' dosages (2.5 to 5 mg/day) of oral torasemide have been used to treat essential hypertension, both as monotherapy and in combination with other antihypertensive agents. When used in these dosages, torasemide lowered diastolic blood pressure (DBP) to below 90mm Hg in 8 to 12 weeks in 70 to 80% of patients. With dose doubling, this level of efficacy occurred in more than 90% of hypertensive patients. Clinical trials have established that blood pressure can be maintained at this level for at least 1 year with low dose torasemide. Torasemide is well tolerated in dosages up to 20 mg/day for at least 1 year. The most commonly reported adverse effects are those associated with loop diuretics in general. These include transient hypokalaemia, hyperuricaemia, dizziness, headache, gastrointestinal disturbances, orthostatic hypotension and fatigue. Adverse effects are comparable with those of other diuretics and rarely necessitate drug withdrawal.

show abstract

“…• Тиазидные или петлевые диуретики рекомендуются для усиления гипотензивной терапии при недостаточной антигипертензивной эффективности применения комбинации иАПФ (БРА вместо иАПФ, но не вместе! ), БАБ и АМКР у пациентов с ХСН и артериальной гипертонией (IА) [344][345][346].…”

Section: артериальная гипертонияunclassified

Eurasian Association of Cardiology (Eac)/ National Society of Heart Failure and Myocardial Disease (Nshfmd) Guidelines for the Diagnosis and Treatment of Chronic Heart Failure (2020)

Терещенко¹,

Жиров²,

Uskach

et al. 2020

Evrazijskij kardiologičeskij žurnal

View full text Add to dashboard Cite

Disclaimer The EAC/NSHFMD Guidelines represent the views of the EAC and NSHFMD, and were produced after careful consideration of the scientific and medical knowledge, and the evidence available at the time of their publication. The EAC and NSHFMD is not responsible in the event of any contradiction, discrepancy, and/or ambiguity between the EAC/NSHFMD Guidelines and any other official recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the EAC/NSHFMD Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic, or therapeutic medical strategies; however, the EAC/NSHFMD Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do the EAC/NSHFMD Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient’s case in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.Members of the Working Group confirmed the lack of financial support/ conflict of interest. In the event of a conflict of interest being reported, the member (s) of the Working Group was (were) excluded from the discussion of sections related to the area of conflict of interest.E.B. Wataman professor, Dr. of Sci. (Med.) (Moldova); E.K. Kurlyanskaya, Cand. of Sci. (Med.) (Belarus); A.M. Noruzbaeva professor (Kyrgyzstan); V.A. Azizov professor (Azerbaijan); Zelveyan P.A., Dr. of Sci. (Med.) (Armenia)

show abstract

Comparison of Torasemide and Indapamide in the Treatment of Essential Hypertension

Cited by 4 publications

References 0 publications

Torasemide, but not frusemide, increases intracellular cAMP and cGMP content in the aorta of the renal hypertensive rat

Torasemide, but not frusemide, increases intracellular cAMP and cGMP content in the aorta of the renal hypertensive rat

Benefits and Risks of Torasemide in Congestive Heart Failure and Essential Hypertension

Eurasian Association of Cardiology (Eac)/ National Society of Heart Failure and Myocardial Disease (Nshfmd) Guidelines for the Diagnosis and Treatment of Chronic Heart Failure (2020)

Contact Info

Product

Resources

About